This study looked at over one thousand two hundred patients who received immune checkpoint inhibitors for various cancers. The main goal was to see if having diabetes changed how well these powerful drugs worked. Results showed that patients with diabetes had a much higher risk of dying during treatment compared to those without the condition.
When doctors analyzed how long the cancer stayed under control, the answer was less clear. Some smaller studies suggested worse results for diabetic patients, but larger studies did not always show this difference. This means the data is not consistent enough to say for sure that diabetes hurts cancer control.
The researchers also noted several weaknesses in the available information. Because the data came from past medical records, there could be errors or missing details. Different types of cancer were mixed together, which might hide specific effects. Therefore, doctors should not change how they treat patients yet based on this single review.